Small-molecule direct thrombin inhibitors: 1997 - 2000
- 1 May 2001
- journal article
- Published by Taylor & Francis in Expert Opinion on Therapeutic Patents
- Vol. 11 (5), 721-738
- https://doi.org/10.1517/13543776.11.5.721
Abstract
Thrombin is a multifunctional enzyme whose properties have been well documented. Because of the importance of this enzyme in the blood coagulation cascade, thrombin has emerged as an attractive target for the treatment and prevention of several cardiovascular disorders. Over the years several strategies have emerged in the search for a small-molecule direct thrombin inhibitor. Research efforts in the field have focused on covalent and non-covalent peptides, as well as peptide surrogates that bind to the active site of the enzyme. Recently, thrombin inhibitors lacking the conventional hydrogen bonding capabilities of the aforementioned subtypes have received an increased amount of attention. This review accounts the patent literature covering these classes of thrombin inhibitors since the last review in 1997.Keywords
This publication has 33 references indexed in Scilit:
- Hemostasis in the 21st century.The Netherlands Journal of Medicine, 1999
- Direct thrombin inhibitors: current status and future prospectsExpert Opinion on Investigational Drugs, 1999
- Small, noncovalent serine protease inhibitorsMedicinal Research Reviews, 1999
- Chapter 9. Anticoagulants: Thrombin and Factor Xa InhibitorsPublished by Elsevier ,1999
- Molecules in focus ThrombinThe International Journal of Biochemistry & Cell Biology, 1998
- Successors to heparin: New antithrombotic agentsAmerican Heart Journal, 1997
- Small-molecule direct thrombin inhibitorsExpert Opinion on Therapeutic Patents, 1997
- Chapter 11. Future Antithrombotic TherapyPublished by Elsevier ,1992
- Thrombin structure and functionBlood Coagulation & Fibrinolysis, 1991
- Drug Interactions with WarfarinDrugs, 1983